Effects of nintedanib on the microvascular architecture in a lung fibrosis model

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Ganesh Raghu, Harold R. Collard, Jim Egan et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 7.3K citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Ulrich Costabel, Moisés Selman et al. · New England Journal of Medicine · 2011 · 1.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Frank Hilberg, Gerald J. Roth, Martin Krššák et al. · Cancer Research · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Standardized Quantification of Pulmonary Fibrosis in Histological Samples

Ralf‐Harto Hübner, Wolfram Gitter, Nour Eddine El Mokhtari et al. · BioTechniques · 2008 · 829 citations · Full text

Medicine, Pathobiology, Pathology +15